Yoichi Ozawa

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE · 2019 · 442 citations · Full text

Flow Cytometric Analysis, Antitumor Activity, Immunology +25

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

Takeshi Yoshida, Yoichi Ozawa, Takayuki Kimura et al. · British Journal of Cancer · 2014 · 352 citations · Full text

Epithelial-mesenchymal Transition, Breast Oncology, Oncology +13

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Takayuki Kimura, Yu Kato, Yoichi Ozawa et al. · Cancer Science · 2018 · 327 citations · Full text

Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle

Takashi Owa, Hiroshi Yoshino, Tatsuo Okauchi et al. · Journal of Medicinal Chemistry · 1999 · 323 citations

Tumor Biology, Medicinal Chemistry, Drug Targeting +15

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

Yasuhiro Funahashi, Kiyoshi Okamoto, Yusuke Adachi et al. · Cancer Science · 2014 · 275 citations · Full text

Breast Oncology, Biological Microenvironments, Pathology +19